SUBSCRIBE
SUBSCRIBE
News   Drug Development

Novartis AG’s Onbrez Better Than Pfizer Inc.'s Drug Spiriva In COPD

November 3, 2010 | 
1 min read
ZURICH, Nov 3 (Reuters) - Swiss drugmaker Novartis AG's (NOVN.VX) lung drug Onbrez reduced breathlessness more effectively than Pfizer's (PFE.N) Spiriva in patients with a deadly lung disease, a late-stage trial found.
Clinical research Phase III Europe
Pfizer Novartis
MORE ON THIS TOPIC
halftone magazine style banner, dislike, negative rating, hand thumbs down
FDA
FDA Drops Another Cache of Heavily Redacted Rejection Letters, Promises Future ‘Real-Time’ Access
September 4, 2025
 · 
4 min read
 · 
Annalee Armstrong
IN PARTNERSHIP WITH TACONIC BIOSCIENCES
The ‘Research Safety Net’ Saving Scientists from Funding Crisis
September 4, 2025
 · 
1 min read
 · 
Lori Ellis
Sea wave. Hand drawn realistic vector illustration in oriental vintage ukiyo-e style.
RNA editing
Wave Crashes Despite Successful RNA Editing in AATD Study
September 4, 2025
 · 
2 min read
 · 
Tristan Manalac
Contemporary art collage of human hands holding a arrow pointing up, graphs and diagrams. Concept of profit, making money, business. Copy space.
Cardiovascular disease
Ionis’ Tryngolza Hits ‘Best-Case Scenario’ in Late-Stage Triglyceride Study
September 3, 2025
 · 
2 min read
 · 
Tristan Manalac